SGEN Stock Charts

Quarterly

Annual

Unit: USD	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31

operating activities:
net income	-215,789,000	-211,528,000	-174,737,000	-148,171,000	-190,816,000	-134,827,000	-136,494,000	-174,628,000	25,830,000	-91,913,000	-79,238,000	-13,329,000	-119,805,000	-67,446,000	76,273,000	-111,715,000	-59,201,000	50,021,000	-56,360,000	-59,990,000	-55,138,000	-31,752,000	-32,743,000	-20,478,000	-24,856,000	-26,438,000	-47,502,000	-21,690,000	-26,684,000	-15,566,000	-17,590,000	-16,301,000	-15,671,000	-23,686,000	-6,899,000	-16,264,000	-10,596,000	-13,652,000	-17,236,000	-12,298,000	-27,165,000	-40,685,000	-51,506,000	-32,674,000	-34,546,000	-34,856,000	-8,323,000	11,460,000	-12,117,000	-19,827,000	-22,471,000	-27,268,000	-30,597,000	-21,764,000	-16,028,000	-17,112,000	-14,941,000	-14,613,000	-10,550,000	-8,828,000	-10,020,000	-8,649,000	-8,643,000	-8,703,000	-7,349,000	-6,171,000	-8,360,000	-7,553,000	-10,570,000	-9,368,000	-8,836,000	-6,665,000	-5,436,168	-5,183,399	-5,504,827	-5,961,606	-5,814,381	-5,088,136	-6,266,085	-5,991,936
adjustments to reconcile net income to net cash used by operating activities
share-based compensation	131,343,000	93,216,000	63,939,000	64,317,000	58,938,000	54,129,000	43,913,000	52,109,000	47,602,000	27,875,000	26,157,000	25,715,000	25,693,000	20,813,000	15,517,000	16,838,000	15,903,000	15,906,000	17,528,000	14,465,000	15,426,000	12,760,000	12,103,000	12,182,000	13,116,000	11,148,000	9,837,000	7,735,000	11,601,000	10,279,000	9,435,000	9,304,000
depreciation	13,189,000	12,444,000	12,423,000		11,775,000	11,465,000	11,402,000
amortization of intangible assets	5,817,000	5,754,000	5,690,000	5,816,000	5,817,000	5,753,000	5,691,000	5,816,000
amortization of right-of-use assets	3,985,000	3,375,000	3,979,000		3,301,000	3,188,000	2,952,000			2,424,000	2,412,000	2,421,000
amortization of premiums, accretion of discounts, and (gains) losses on debt securities	-11,291,000	-11,768,000	-11,274,000	-5,936,000	-1,613,000	300,000	184,000	1,241,000						-873,000
losses on equity securities	-491,000	3,004,000	237,000
deferred income taxes	286,000	338,000	211,000	774,000	336,000	-712,000	155,000
inventory write-off	0
changes in operating assets and liabilities
accounts receivable	-45,507,000	-90,271,000	6,135,000	-15,157,000	-48,714,000	-37,032,000	-11,753,000	-2,087,000	-45,683,000	-8,054,000	-25,309,000	-10,674,000	6,239,000	-2,544,000	-31,397,000	-17,531,000	5,658,000	-18,492,000	1,747,000	-11,759,000	3,193,000	-7,379,000	-5,350,000	538,000	10,568,000	-18,248,000	4,337,000	-10,339,000	4,569,000	-8,912,000	2,991,000	-8,388,000	-300,000	18,461,000	-2,948,000	-11,278,000	1,713,000	-3,603,000	25,028,000	-1,626,000	-39,508,000	-4,436,000	-2,390,000	10,658,000	-4,017,000	-82,000	-1,365,000	66,307,000	-76,128,000	2,023,000	5,863,000	-3,694,000	-1,591,000	997,000	-227,000	-1,377,000	-600,000	-403,000	-1,252,000	-2,835,000	-164,000	25,000	-402,000	326,000	189,000	-230,000	266,000	569,000	-830,000	58,000	466,000	-345,000	205,835	88,030	-811,376	63,511				30,027
inventories	-44,334,000	-55,684,000	-50,483,000	-62,241,000	-45,616,000	-43,607,000	-75,084,000	-19,288,000	6,102,000	-18,884,000	-5,914,000	-13,997,000	21,933,000	-4,239,000	982,000	-11,937,000	859,000	8,410,000	-8,524,000	7,401,000	3,521,000	30,000	-11,625,000	-3,087,000	-12,448,000	2,974,000	-4,420,000	382,000	-5,910,000	-7,050,000	-1,447,000	-1,971,000	-1,069,000	12,657,000	-4,929,000	4,015,000	-3,451,000	-8,599,000	-9,944,000	-6,284,000	-6,041,000
prepaid expenses and other assets	-42,477,000	-11,250,000	541,000	-5,006,000	25,949,000	-12,726,000	-24,523,000	-8,519,000	-955,000	-2,861,000	-1,127,000	7,402,000	-18,750,000	9,175,000	6,537,000	-11,529,000	-86,000	3,435,000	-5,964,000	445,000	-159,000	-3,412,000	1,865,000	-2,672,000	-4,897,000	3,506,000	-4,213,000	3,652,000	-4,031,000	-94,000	-453,000	-654,000
lease liability	-3,306,000	-2,982,000	-3,969,000		-3,309,000	-3,375,000	-5,158,000		-2,027,000	-1,678,000	-471,000	-2,484,000
other liabilities	172,752,000	43,583,000	-102,335,000	74,426,000	95,554,000	81,375,000	-30,876,000	-155,849,000	15,642,000	32,488,000	11,731,000	-12,410,000
net cash used by operating activities	-35,823,000	-175,245,000	-249,643,000		-85,729,000	-71,770,000	-216,812,000		-11,851,000	-60,646,000	-34,013,000	-57,227,000	-24,285,000	-11,116,000	-20,971,000	-147,164,000
capex	-43,930,000	-49,230,000	-38,655,000		-15,934,000	-14,764,000	-17,397,000		-18,990,000	-18,432,000	-20,797,000	-12,534,000	-6,278,000	-5,451,000	-4,817,000	-4,673,000
free cash flows	-79,753,000	-224,475,000	-288,298,000		-101,663,000	-86,534,000	-234,209,000		-30,841,000	-79,078,000	-54,810,000	-69,761,000	-30,563,000	-16,567,000	-25,788,000	-151,837,000
investing activities:
purchases of securities	-573,852,000	-507,313,000	-618,151,000	-402,022,000	-570,915,000	-833,387,000	-655,940,000	-1,035,443,000	-326,856,000	-518,565,000	-69,074,000	-78,481,000	-137,978,000	-131,677,000	-180,051,000	-62,628,000
proceeds from maturities of securities	760,500,000	690,000,000	891,500,000	397,000,000	656,000,000	1,035,000,000	700,000,000	1,050,000,000	411,000,000	155,000,000	92,500,000	127,500,000	128,001,000	60,699,000	90,000,000	120,022,000
payments for lessor-owned assets	-227,000	-369,000	-2,358,000	-2,223,000	-4,180,000
purchases of property and equipment	-43,930,000	-49,230,000	-38,655,000	-29,245,000	-15,934,000	-14,764,000	-17,397,000	-13,575,000	-18,990,000	-18,432,000	-20,797,000	-12,534,000	-6,278,000	-5,451,000	-4,817,000	-4,673,000	13,893,000	-5,059,000	-22,973,000	-14,583,000	-8,950,000	-8,201,000	-3,351,000	-7,333,000	-4,366,000	-4,069,000	-2,586,000	-2,371,000	-7,395,000	-2,641,000	-3,999,000	-3,141,000	-7,361,000	-6,402,000	-2,137,000	-6,254,000	-5,806,000	-2,353,000	-1,271,000	-1,055,000	-6,236,000	-3,431,000	-1,282,000	-303,000	-415,000	-876,000	-1,204,000	-1,053,000	-706,000	-677,000	-1,320,000	-1,886,000	-910,000	-1,303,000	-1,557,000	-1,114,000	-1,957,000	-908,000	-532,000	-886,000	-522,000	-452,000	-532,000	-174,000	-212,000	-597,000	-182,000	-411,000	-362,000	-1,636,000	-2,947,000	-778,000	-235,883	-109,114	-107,787	-136,216
net cash from investing activities	142,491,000	133,088,000	232,336,000		64,971,000												19,879,000	-71,341,000	161,520,000	19,803,000	-19,089,000	-42,381,000	100,232,000	29,431,000	-494,965,000	43,704,000	55,028,000	20,383,000	26,282,000	18,230,000	-4,042,000	-3,848,000	-63,411,000	49,402,000	-3,984,000	-6,643,000	-57,779,000	7,516,000	-15,893,000	-14,020,000	5,452,000	71,396,000	47,298,000	-121,592,000	18,439,000	-17,799,000	33,559,000	-45,769,000	-37,541,000	-71,532,000	-3,615,000	-34,730,000	31,954,000	-2,887,000	-64,898,000	-31,997,000	39,062,000	15,657,000	-4,745,000	-45,901,000	-9,127,000	301,000	-10,829,000	8,894,000	7,357,000	3,768,000			317,000	2,790,000	8,545,000	-51,982,000	-3,492,415	-38,357,076	4,349,194	6,664,297	4,976,756
financing activities:
proceeds from exercise of stock options and employee stock purchase plan	15,522,000	13,815,000	42,240,000	65,347,000	18,389,000	14,960,000	26,664,000	22,347,000	27,793,000	23,306,000	11,226,000	26,826,000	3,269,000	28,846,000	11,145,000	11,905,000	15,320,000	10,608,000	4,548,000	10,835,000	11,787,000	12,911,000	4,800,000	5,698,000	2,102,000	5,298,000	7,971,000	12,392,000	1,260,000	4,898,000	2,244,000	7,786,000		12,673,000	3,995,000	16,786,000		11,389,000	10,038,000	7,584,000		2,824,000	6,548,000	3,390,000		1,598,000				3,443,000	424,000	693,000		2,502,000	267,000	1,147,000		2,634,000	1,411,000	876,000	43,000	183,000
employee taxes paid related to net share settlement of stock-based awards	0	0	-12,303,000
net cash from financing activities	15,522,000	13,815,000	29,937,000	65,347,000	18,389,000	14,960,000	26,664,000	22,347,000	27,793,000	571,997,000	11,226,000	26,826,000	3,269,000	28,846,000	11,222,000	670,070,000	15,320,000	10,608,000	4,548,000	10,835,000	11,787,000	12,911,000	4,800,000	5,698,000	2,102,000	531,916,000	7,971,000	12,392,000	1,260,000	4,898,000	2,244,000	7,786,000	1,745,000	12,673,000	3,995,000	16,786,000	6,713,000	11,389,000	10,038,000	7,584,000	7,169,000	2,824,000	6,483,000	171,508,000	1,880,000	1,598,000	2,859,000	1,040,000	186,000	131,657,000	11,819,000	53,225,000	70,000	2,502,000	267,000	98,775,000	1,683,000	2,634,000	1,411,000	876,000	43,000	183,000	43,408,000	289,000	29,000	460,000	62,000	601,000	857,000	299,000	97,000	62,376,000	7,772,711	41,384,766	-228,987	74,510	1,498	69,596	3,504,984	3,071,931
effect of exchange rate changes on cash, cash equivalents, and restricted cash	-2,290,000	566,000	920,000	5,699,000	-4,084,000
net increase in cash, cash equivalents, and restricted cash			13,550,000	-44,884,000
cash, cash equivalents, and restricted cash at beginning of period	0	0	323,486,000		0
cash, cash equivalents, and restricted cash at end of period	119,900,000	-27,776,000	337,036,000		-6,453,000
net decrease in cash, cash equivalents, and restricted cash
adjustments to reconcile net income to net cash (used) provided by operating activities
depreciation and amortization									9,628,000	4,241,000	4,961,000	4,944,000	6,987,000	5,212,000	6,823,000	7,010,000	7,876,000	6,178,000	5,431,000	4,784,000	4,764,000	4,624,000	4,416,000	4,230,000	3,745,000	3,725,000	3,612,000	3,423,000	3,382,000	3,209,000	3,062,000	2,837,000	2,558,000	2,216,000	2,114,000	1,727,000	1,597,000	1,539,000	1,529,000	1,494,000	1,391,000	1,008,000	896,000	875,000	938,000	934,000	874,000	816,000	846,000	856,000	820,000	738,000	927,000	879,000	835,000	774,000	669,000	651,000	635,000	593,000	616,000	606,000	608,000	588,000	600,000	590,000	577,000	566,000	569,000	481,000	355,000	339,000	332,354	333,164	330,372	330,110	334,917	318,149	297,626	280,781
amortization of right-of-use-assets
gain on equity securities
gain on disposals of property and equipment
changes in operating assets and liabilities:
lease liabilities
net cash (used) provided by operating activities								-283,383,000
proceeds from sales of securities													0	14,869,000	77,014,000	48,469,000
net cash provided (used) by investing activities							26,663,000	982,000			2,629,000	36,485,000	-16,255,000	-61,560,000	-17,854,000	-496,961,000
net proceeds from issuance of common stock									0				0	0	77,000	658,165,000					0				0												0	0	0	0	0	0	-65,000	168,118,000					0	128,214,000	11,395,000	52,532,000	0	0	0	97,628,000					0	0	42,857,000	289,000	29,000	460,000	62,000	601,000	857,000	299,000	97,000	62,376,000	7,772,244	504,640	4,606	74,510	1,498	69,596	3,504,984	3,071,931
cash, cash equivalents, and restricted cash at beginning of year
cash, cash equivalents, and restricted cash at end of year
losses (gains) on equity securities					2,669,000	4,299,000	2,779,000
effect of exchange rate changes on cash and cash equivalents							-353,000	-285,000
net decrease in cash and cash equivalents							-163,838,000																								-5,981,000	-19,304,000			-7,302,000	-19,729,000												-154,000
cash and cash equivalents at beginning of period							424,834,000			0	0	78,186,000		0	0	160,945,000		0	0	108,673,000		0	0	102,255,000		0	0	56,927,000		0	0	64,116,000		0	0	54,663,000		0
cash and cash equivalents at end of period							260,996,000			129,354,000	-20,158,000	84,270,000		-43,830,000	-27,603,000	186,890,000		-68,964,000	121,337,000	75,767,000		-61,059,000	72,541,000	119,547,000		535,061,000	16,442,000	62,571,000		11,337,000	-5,981,000	44,812,000		91,897,000	-7,302,000	34,934,000		-5,829,000
adjustments to reconcile net income to net cash provided (used) by operating activities
(gain) loss on disposals of property and equipment
deferred revenue									-7,028,000	-9,974,000	-9,908,000	-6,690,000	-8,899,000	-7,735,000	-8,929,000	-8,350,000	-6,737,000	-3,961,000	-4,112,000	-2,068,000	-8,634,000	-8,491,000	-10,476,000	-9,030,000	-12,999,000	-7,480,000	-14,371,000	-13,526,000	-11,184,000	-173,000	-4,139,000	-7,685,000	7,923,000	6,892,000	-6,945,000	-2,043,000	38,024,000	965,000	-2,076,000	-1,804,000	633,000	-5,100,000	5,186,000	7,718,000	10,629,000	12,915,000	-11,937,000	-31,807,000	73,605,000	-4,668,000	-3,308,000	2,940,000	-598,000	2,703,000	1,038,000	4,497,000	15,659,000	787,000	-541,000	64,195,000	-1,245,000	-1,587,000	-989,000	-1,623,000	-1,418,000	-1,593,000	2,141,000	-116,000	1,583,000	-647,000	1,704,000	2,344,000	2,560,321	-364,663	-240,330	-325,328	10,197	225,000
net increase in cash and cash equivalents								-260,339,000	81,096,000			6,084,000	-37,271,000	-43,830,000	-27,603,000	25,945,000	32,805,000	-68,964,000	121,337,000	-32,906,000	-22,356,000	-61,059,000	72,541,000	17,292,000	-511,819,000	535,061,000	16,442,000	5,644,000	6,759,000				-55,413,000				-268,000	-5,829,000	7,417,000	-34,291,000	-24,471,000	32,308,000	18,328,000	40,342,000	-1,644,000	-26,722,000			-53,574,000			-59,000	6,387,000			55,479,000	46,245,000	8,324,000	-12,433,000	8,371,000	-18,774,000	-7,254,000	23,456,000	553,000	250,000	-3,324,000	3,827,000	758,000	-5,315,000	-3,542,000	1,616,000	7,261,000	1,593,011			1,272,017	285,003
cash and cash equivalents at beginning of year																																								87,634,000
cash and cash equivalents at end of year																																								53,343,000
gains on equity securities														23,765,000
loss on disposals of property and equipment
income tax benefit on unrealized loss on available-for-sale securities
acquisition of manufacturing facility
acquisition of cascadian therapeutics, inc., net of cash acquired													0	0	0	-598,151,000
(gains) losses on equity securities										5,690,000	42,693,000	-38,125,000
net cash used by investing activities
amortization of premiums, accretion of discounts and (gains) losses on debt securities
other long-term liabilities													646,000	613,000
accounts payable and accrued liabilities													30,924,000	12,143,000	18,886,000	-28,877,000	12,890,000	17,286,000	7,466,000	-18,544,000	21,572,000	1,856,000	8,150,000	-1,639,000	7,172,000	-9,763,000	6,012,000	3,118,000	8,394,000	6,668,000	3,907,000	-521,000	4,176,000	3,870,000	3,812,000	-10,365,000	13,605,000	-9,629,000	11,589,000	-12,483,000	14,761,000	4,451,000	8,443,000	-390,000	-1,197,000	6,076,000	5,980,000	-4,572,000	-2,450,000	2,787,000	1,571,000	1,709,000	962,000	3,871,000	1,758,000	-420,000	1,453,000	1,597,000	1,855,000	-650,000	192,000	183,000			264,000	-749,000	765,000	-50,000	1,138,000	778,000	1,000	1,172,000	-1,376,698	1,127,127	-480,759	265,330
gain on immunomedics warrant derivative
operating activities
amortization of premiums, accretion of discounts and loss on investments																-146,000				1,836,000
deferred rent and other long-term liabilities																248,000	-52,000	84,000	-72,000	-114,000	-27,000	-396,000	-235,000	-224,000	-194,000	-356,000	-177,000	-194,000	-105,000	-293,000	-141,000	-195,000	-197,000	-152,000	-153,000	-104,000	891,000	-94,000	-375,000	294,000	1,727,000	288,000	214,000	18,000	57,000	42,000	71,000	28,000	104,000	24,000	1,019,000	101,000	143,000	150,000	-179,000	997,000
unrealized losses on equity securities																18,825,000
investing activities
financing activities
adjustments to reconcile net income to net cash from operating activities
amortization of premiums, accretion of discounts and (gain) loss on investments
net gain on immunomedics warrant derivative
income tax benefit on unrealized gain on available-for-sale securities																	-27,942,000
net cash from operating activities																	-2,394,000	-8,231,000	-44,731,000	-63,544,000	-15,054,000	-31,589,000	-32,491,000	-17,837,000	-18,956,000	-40,559,000	-46,557,000	-27,131,000	-20,783,000	-11,791,000	-4,183,000	-23,242,000	6,253,000	29,822,000	-7,313,000	-29,872,000	50,798,000	-24,734,000	13,272,000	-27,855,000	-37,092,000	-41,912,000	-35,453,000	-9,574,000	-21,963,000	-10,521,000	-5,257,000	44,575,000	-16,219,000	-14,656,000	-12,354,000	-18,554,000	-25,637,000	-10,110,000	-15,584,000	-11,299,000	5,500,000	-9,967,000	-9,099,000	53,396,000	-9,690,000	-7,738,000	-9,123,000	-8,630,000	-7,136,000	-7,552,000	-4,608,000	-6,176,000	-6,489,000	-6,631,000	-7,026,000	-3,133,000	-2,687,285	-3,623,981	-5,944,944	-5,466,790
purchases of available-for-sale securities
proceeds from maturities of available-for-sale securities
proceeds from sales of available-for-sale securities
purchase of cost-method investment																					0	0			0	0
purchases of securities available-for-sale																		-191,782,000	-45,507,000	-208,370,000
proceeds from maturities of securities available-for-sale																		125,500,000	230,000,000	182,700,000
proceeds from sales of securities available-for-sale																		0	0	60,056,000																		5,000,000	0	5,825,000
amortization of premiums, accretion of discounts and gain on investments																																	353,000	297,000	459,000	774,000	804,000	754,000
purchases of securities available for sale																					-160,439,000	-114,180,000	-216,417,000	-112,736,000	-577,599,000	-55,527,000	-58,191,000	-63,346,000	-120,195,000	-97,629,000	-105,243,000	-128,207,000	-142,739,000	-130,312,000	-139,042,000	-71,089,000	-158,672,000	-91,131,000	-131,622,000	-123,641,000	-95,316,000	-60,454,000	-84,720,000	-238,899,000	-124,676,000	-118,879,000	-63,937,000	-146,107,000	-167,475,000	-122,649,000	-55,834,000	-50,882,000	-1,000	-21,097,000	-75,275,000	-57,964,000	-23,497,000	-22,060,000	-57,044,000	-83,316,000
proceeds from maturities of securities available for sale																					150,300,000	80,000,000	320,000,000	149,500,000	87,000,000	103,300,000	90,800,000	86,100,000	152,900,000	118,500,000	105,200,000	127,500,000	86,500,000	186,200,000	137,300,000	70,700,000	107,300,000	96,000,000	117,000,000	104,851,000	107,006,000	141,043,000	133,300,000	117,610,000	143,275,000	99,890,000	98,700,000	101,391,000	130,640,000	51,725,000	52,520,000	17,034,000	32,865,000	12,513,000	11,934,000	27,081,000	62,516,000	36,375,000	52,831,000	38,301,000
proceeds from sales of securities available for sale																					0	0			0	0							0	0	0	0									255,000				0	69,000	1,019,000	1,004,000	0				2,000,000
amortization of premiums and accretion of discounts																						571,000	1,404,000	2,343,000		373,000	328,000	308,000		141,000	192,000	332,000
interest receivable																																	-371,000	393,000	548,000	-268,000	603,000	-617,000	-42,000	-196,000	373,000	178,000	36,000	-446,000	270,000	107,000	1,233,000	-1,042,000	19,000	616,000	42,000	-139,000	181,000	-110,000	-432,000	-769,000	191,000	125,000	-275,000	-260,000	176,000	66,000	-93,000	-10,000	70,000	150,000	-279,000	199,000	-33,000	405,000	-154,000	-366,000	-125,092	-368,019	106,524	87,587	122,703	186,343
investments in other non-current assets
proceeds from exercise of stock options, warrants and employee stock purchase plan
share-based compensation expense																																		8,231,000	6,780,000	6,606,000	7,431,000	6,272,000	5,536,000	6,101,000	5,964,000	5,490,000	4,262,000	4,268,000	4,232,000	3,736,000	3,178,000	3,184,000	3,360,000	3,046,000	2,729,000	2,714,000	3,012,000	2,426,000	2,746,000	2,228,000	2,511,000	2,002,000	2,041,000	1,374,000
prepaid expenses and other current assets																																		643,000	848,000	-2,672,000	177,000	1,930,000	-1,306,000	-1,500,000	1,505,000	-962,000	-1,690,000	-427,000		6,000	4,081,000	-1,226,000		-284,000	238,000	3,463,000																						38,752	39,860	-404,755
purchases of other non-current assets																																		-84,000				0
amortization of discounts, accretion of premiums and gain on investments																																								447,000
amortization of discounts, accretion of premiums and loss on investments
change in other non-current assets																																									-2,000
amortization and accretion on investments																																										1,081,000	1,298,000	827,000	481,000
proceeds from sale of securities available for sale
cash and cash equivalents, at beginning of period																																										0	0	21,127,000	0	0	0	18,486,000	0	0	0	30,800,000	0	0	0	59,644,000	0	0	0	9,137,000	0	0	0	11,156,000	0	0	0	9,645,000	0	0	0	9,625,000	84	0	0	9,180,916	0	0	0	8,293,504
cash and cash equivalents, at end of period																																										32,308,000	18,328,000	61,469,000	-1,644,000	-26,722,000	31,161,000	18,332,000	-53,574,000	45,469,000	-4,150,000	30,741,000	6,387,000	-10,495,000	-80,215,000	115,123,000	46,245,000	8,324,000	-12,433,000	17,508,000	-18,774,000	-7,254,000	23,456,000	11,709,000	250,000	-3,324,000	3,827,000	10,403,000	-5,315,000	-3,542,000	1,616,000	16,886,000	1,593,095	-596,291	-1,824,737	10,452,933	285,003	4,770,915	-2,224,336	6,349,334
other non-current assets																																											-202,000	-1,000	-5,000	1,000	1,000	29,000	27,000
prepaid expenses and other																																																							-5,491,000	-188,000	627,000	-22,000	-812,000	193,000	-346,000	555,000	-916,000	-384,000	216,000	116,000	-66,000	-104,000	1,121,000	920,000	-1,855,000	-317,000
proceeds from exercise of options and warrants to purchase common stock
amortization on investments																																																		826,000	1,143,000	882,000		568,000	396,000	71,000		-75,000	-192,000	-382,000				216,000	285,000	329,000	337,000	284,000	421,000	622,000	737,000	536,000	446,858	341,524			131,796	176,049
amortization of investments																																																1,398,000																												97,752
proceeds from exercise of options to purchase common stock																																																1,040,000
realized losses and amortization on investments
deferred rent																																																									-11,000	-16,000	-8,000	-4,000		-5,000	3,000	6,000	6,000	6,000	13,000	16,000	16,000	17,000	23,000	26,000	26,486	26,363	32,933	36,218	36,218	36,217	42,659	45,880
supplemental disclosures
non-cash investing and financing activities
property and equipment purchase costs accrued
stock-based compensation expense																																																																	2,000	0			80,000	103,000	533,000	153,000	341,163	338,653			524,788	588,806
stock compensation expense																																																														1,291,000	999,000	954,000				10,000
realized loss and amortization on investments																																																														-223,000
purchases of investments																																																														-15,695,000	-56,991,000	-6,823,000	-3,496,000	-8,034,000	-14,720,000	-11,775,000	-22,727,000	-29,321,000	-12,105,000	-61,664,000	-14,469,529	-46,598,834	-3,554,322	-1,874,315
proceeds from sales and maturities of investments																																																														16,448,000	46,694,000	15,891,000				18,519,000
proceeds from sale and maturities of investments																																																																	11,065,000	12,399,000			23,406,000	33,747,000	23,597,000	10,460,000	11,212,997	8,350,872	8,011,303	8,674,828	7,264,208	12,039,551	7,199,004	5,916,950
net proceeds from issuance of preferred stock and warrants
collection of notes receivable from stockholders
adjustments to reconcile net income to net cash from operating activities:
realized gain on sale of investments																																																																		0			0	0	0	-10,000	-487
non-cash investing and financing activities:
decrease in deferred stock compensation																																																																							-437,000	-137,000
property and equipment purchase cost accrued
loss on disposal of property and equipment																																																																				2,000
realized (gain) loss on investments																																																																				1,000
net cash from (provided by) investing activities																																																																				6,333,000
increase in deferred stock compensation																																																																					0							-86,493	-26,575	-230,192	-15,089	370,152
net proceeds from issuance of series a convertible preferred stock and common stock warrants
collection of notes receivable
prepaid private placement costs
leasehold improvement construction costs accrued																																																																							-392,000	781,000
gain on disposal of property and equipment																																																																													0
proceeds from disposal of property and equipment
collection of note receivable from stockholder
supplemental disclosure of cash flow information
non-cash investing and financing activities increase in deferred stock compensation
stock-based compensation																																																																												344,391
realized (gain) loss on sale of investments
proceeds from subscription receivable
net proceeds from issuance of series b preferred stock
prepaid public offering costs
book overdraft
issuance of common stock in exchange for notes receivable
accounts payable																																																																														-42,967	-735,624	1,031,493
accrued liabilities																																																																														444,909
conversion of preferred stock to common stock
amortization of deferred compensation																																																																																879,527
realized loss on sale of investments
amortization (accretion) on investments																																																																																195,629
cash flows from operating activities
realized loss on sale of securities
amortization/ accretion on investments
common stock bonus provided to employees
prepaid expenses, reimbursable costs and other assets
cash flows from investing activities
purchase of property and equipment
cash flows from financing activities
net proceeds from issuance of series a preferred stock
supplemental disclosure of cash information
issuance of series b preferred stock for subscription notes receivable

The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.